A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age

► As part of a postmarketing commitment, LAIV safety was studied in approximately 20,000 eligible adults over 5 influenza seasons. ► Rate differences of medically attended events suggested no safety signal associated with LAIV. ► No serious adverse event occurred at a significantly higher rate after LAIV. ► No significant adverse outcomes were identified among eligible adults after LAIV.